HC Wainwright Reiterates Neutral Rating for Windtree Therapeutics (NASDAQ:WINT)

Windtree Therapeutics (NASDAQ:WINT)‘s stock had its “neutral” rating restated by HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $7.00 price objective on the stock.

Windtree Therapeutics Stock Performance

Shares of WINT opened at $0.39 on Wednesday. The stock has a 50-day simple moving average of $0.81 and a 200-day simple moving average of $3.73. Windtree Therapeutics has a 1 year low of $0.35 and a 1 year high of $16.74. The stock has a market capitalization of $3.49 million, a PE ratio of -0.02 and a beta of 0.54.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.